Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment
The purpose of the study is to test the hypothesis that ultrasound imaging and spectroscopy may be used as a predictive marker of advanced tumour response to neoadjuvant treatment consisting of chemotherapy or concurrent…
- Trial name
- NCT06193122
- Testing
- Ultrasound imaging 3D and Spectroscopy
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, HER2-positive Breast Cancer
Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade
This study aims to identify HER2-positive early-stage breast cancer patients who could benefit from neoadjuvant treatment using PHESGO™ (pertuzumab and trastuzumab) without chemotherapy.
- Trial name
- CHERRY-PICK (NCT06068985)
- Testing
- PHESGO
- Where
- 8 sites in Brazil
- Volunteers
- 63 people
- Sponsor
- Latin American Cooperative Oncology Group
Breast Cancer, Other Disorders of Bone Density and Structure
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
The purpose of this study is to identify the combined impact on bone loss as well as the incidence of bone fractures in women with estrogen receptor (ER)-positive, early breast cancer treated with an aromatase inhibitor (AI)…
- Trial name
- POCHARBI (NCT01298362)
- Testing
- Aromatase Inhibitors, Chemotherapy
- Where
- Greece
- Volunteers
- 290 people
- Sponsor
- Hellenic Breast Surgeons Society
HER2-positive Breast Cancer
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Although there is a certain risk of recurrence of HER2-positive small tumors, the overall prognosis is relatively good. In order to further reduce the toxicity and side effects of treatment and explore the best strategy for…
- Trial name
- NCT06992882
- Testing
- Capecitabine, Paclitaxel
- Where
- China
- Volunteers
- 2,306 people
- Sponsor
- Fudan University
Breastcancer
Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer
Postmastectomy radiotherapy (PMRT) is unequivocally beneficial in reducing the recurrences as well as improving survival in node positive breast cancer patients.
- Trial name
- PMRT-NNBC (NCT02992574)
- Testing
- Post Mastectomy Radiation therapy
- Where
- 7 sites in India
- Volunteers
- 1,022 people
- Sponsor
- Tata Memorial Centre
Breast Cancer
Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00562718
- Testing
- capecitabine, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes
Omission of SLNB in CN0 Early Breast Cancer
The OMSLNB trial adopts a prospective, single-arm, non-inferiority, phase-II, open-label study design. Patients with unilateral invasive breast cancer （tumor ≤3cm） and assessed as cN0 will be eligible for inclusion, enrolled…
- Conditions
- Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node
- Trial name
- NCT05935150
- Testing
- Omit SLNB
- Where
- China
- Volunteers
- 311 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cardiotoxicity, Breast Cancer
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate…
- Conditions
- Cardiotoxicity, Breast Cancer, Chemotherapy Induced Systolic Dysfunction
- Trial name
- EARLY-CATCH (NCT04046315)
- Testing
- CMR
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Radboud University Medical Center
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Breast Cancer
Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer
Through the investigators' Breast Care Center at the University of Michigan Comprehensive Cancer Center, the investigators treat approximately 75 patients per year with neoadjuvant chemotherapy.
- Trial name
- NCT02455882
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan
Breast Cancer, Fatigue
Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer
In order to determine the acceptability of a breast cancer-specific cognitive behavioral therapy intervention, as well as to obtain preliminary data to assess efficacy in managing symptoms, the investigators will ask 45 breast…
- Conditions
- Breast Cancer, Fatigue, Insomnia, Pain
- Trial name
- PROSPECT (NCT02495155)
- Testing
- PROSPECT
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Michigan
Breast Cancer
Phase II Study of Single Agent Lenvatinib
The Investigators hypothesize that single agent lenvatinib has biological activity in estrogen receptor positive breast cancer, and that the effects are more pronounced in patients with positive RET expression in the tumor.
- Trial name
- NCT03168074
- Testing
- lenvatinib
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Metastatic Breast Cancer in the Liver
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
The purpose of this study is to further use DCE-MRI and ivim-dwi to predict the chemotherapy sensitivity of liver metastasis of breast cancer at an early stage, and to predict the treatment response of tumor at an early stage by…
- Trial name
- DreaminLMBC (NCT05550090)
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Triple -Negative Breast Cancer
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Eligible patients was assigned in a 1:1 ratio to receive either low-dose capecitabine maintenance (intervention group) which is newly diagnostic to be planned to receive capecitabine after finishing the standard adjuvant…
- Trial name
- NCT07143097
- Testing
- capecitabine
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Beni-Suef University
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Breast Cancer, Early-stage Breast Cancer
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage…
- Conditions
- Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- NCT06001762
- Testing
- Abemaciclib, Tamoxifen, Anastrozole
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
This clinical trial studies how well ultrasound/photoacoustic/elasticity (US/PA/E) imaging works for early identification of tumor response in patients with stage II-III triple-negative breast cancer receiving immunotherapy and…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07862751
- Testing
- Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
HER2-positive Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with her2 enriched subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04750122
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safety of giredestrant (A) versus giredestrant plus triptorelin (B) versus…
- Trial name
- PREcoopERA (NCT05896566)
- Testing
- Giredestrant, Triptorelin, Anastrozole
- Where
- 37 sites in France, Germany and 4 more
- Volunteers
- 231 people
- Sponsor
- ETOP IBCSG Partners Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.